HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

DEA Proposal To Schedule Kratom Stirs Wave Of Opposition

This article was originally published in The Rose Sheet

Executive Summary

AHPA and the American Botanical Council are among the opponents of DEA's proposal to schedule the active materials in kratom while NPA supports it, saying kratom products and raw ingredients have not met "the strict standards products and new ingredients must adhere to in order to be marketed to the public."

You may also be interested in...



Unapproved Depression Drug Remains Available In US In Supplements To Treat Opioid Addiction

CSPI says FDA has warned companies about tianeptine, which stimulates opioid receptors and may trigger addiction and withdrawal symptoms. But “tianeptine products continue to be widely available in Alabama and online.”

Opioid Abuse Treatment Claims Prompt FDA Warnings To Two Kratom Marketers

As in previous warnings to kratom supplement marketers linked to opioid addiction treatment claims, FDA tells Cali Botanicals and Kratom NC that HHS in 2017 found opioid abuse was nationwide public health emergency and FDA is targeting products that without approval claim to diagnose, mitigate, prevent, treat or cure opioid addiction. Contract manufacturer Somlabs' GMP problems also were identified in FDA's latest warning letters.

Ohio's Proposed Ban On Sales Marks Kratom Industry's Latest Battlefront

Ohio Board of Pharmacy proposes placing into Schedule I kratom constituent ingredients mitragynine and 7-hydroxymitragynine, a change that would prohibit kratom sales in the state. The board's findings "parrot the false propaganda" of FDA in its "crusade to ban kratom," says the American Kratom Association.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS108728

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel